Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Autolus Therapeutics plc (AUTL)

2.5   0.05 (2.04%) 11-25 13:00
Open: 2.49 Pre. Close: 2.45
High: 2.53 Low: 2.42
Volume: 24,855 Market Cap: 228(M)

Technical analysis

as of: 2022-11-25 1:55:18 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.19     One year: 3.76
Support: Support1: 1.96    Support2: 1.63
Resistance: Resistance1: 2.73    Resistance2: 3.22
Pivot: 2.23
Moving Average: MA(5): 2.37     MA(20): 2.38
MA(100): 2.87     MA(250): 3.46
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 56     %D(3): 43.5
RSI: RSI(14): 50.8
52-week: High: 6.94  Low: 1.96
Average Vol(K): 3-Month: 159 (K)  10-Days: 137 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AUTL ] has closed below upper band by 4.7%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.49 - 2.5 2.5 - 2.51
Low: 2.32 - 2.33 2.33 - 2.34
Close: 2.43 - 2.45 2.45 - 2.47

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Headline News

Wed, 16 Nov 2022
Autolus Therapeutics plc (NASDAQ:AUTL) Sees Significant Decline in Short Interest - MarketBeat

Wed, 16 Nov 2022
Autolus Therapeutics: Near-Term Catalyst And Several Bio Deals Could Shift Momentum - AUTL - Seeking Alpha

Sat, 05 Nov 2022
Autolus Therapeutics Earnings, Revenue Beat in Q3 By Investing.com - Investing.com

Sat, 05 Nov 2022
Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 22% this week, taking three-year losses to 81% - Simply Wall St

Fri, 04 Nov 2022
Autolus Therapeutics plc (AUTL) Q3 2022 Earnings Call Transcript - Seeking Alpha

Wed, 12 Oct 2022
Autolus stock rises as Moderna uses option to license targeting technology for mRNA drug - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 91 (M)
% Held by Insiders 2.592e+007 (%)
% Held by Institutions 16.8 (%)
Shares Short 1,040 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.7102e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -6
Return on Assets (ttm) 585.7
Return on Equity (ttm) -39.9
Qtrly Rev. Growth 2.71e+006
Gross Profit (p.s.) 590.71
Sales Per Share -52.68
EBITDA (p.s.) -8.65752e+007
Qtrly Earnings Growth -1.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -107 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 2.16

Stock Dividends

Dividend 0
Forward Dividend 906850
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.